TELA Bio, Inc. earnings releases TELA

TELA Bio, Inc. last reported quarterly results on Aug 10, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $19.3 million (-4.5% year over year) and diluted EPS of -$0.20. It usually reports 30–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 12, 2026.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 30–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Aug 10, 2026
41 days after quarter end
Q2 FY2026
ended Jun 30, 2026
19
-4.5%
-11
-13.5%
-0.20
+9.1%
Apr 30, 2026
30 days after quarter end
Q1 FY2026
ended Mar 31, 2026
19
+2.9%
-12
-9.0%
-0.21
+16.0%
Nov 13, 2025
44 days after quarter end
Q3 FY2025
ended Sep 30, 2025
21
+9.1%
-9
+17.1%
-0.19
+54.8%
Aug 11, 2025
42 days after quarter end
Q2 FY2025
ended Jun 30, 2025
20
+25.5%
-10
+21.2%
-0.22
+56.9%
May 8, 2025
38 days after quarter end
Q1 FY2025
ended Mar 31, 2025
19
+11.5%
-11
-99.0%
-0.25
-8.7%
Oct 22, 2024
22 days after quarter end
Q3 FY2024
ended Sep 30, 2024
19
+25.9%
-10
+5.3%
-0.42
+6.7%
Aug 12, 2024
43 days after quarter end
—
ended Jun 30, 2024
—
—
—
May 9, 2024
39 days after quarter end
—
ended Mar 31, 2024
—
—
—

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
TELA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Malvern, PA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1561921

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.